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The arsenical compound N-phenylglycineamide-p-arsonic acid, the 
toxic action of which has been described in the preceding paper, exer- 
cises a powerful therapeutic effect in experimental trypanosomiasis of 
laboratory animals.  Trypanosomiasis as it occurs in mice and rats is 
chiefly  characterized  by  the  constant  and  progressively increasing 
number of trypanosomes in the peripheral blood stream, by the usual 
lack of any clinical manifestations, and by the relatively early death 
of the infected animal.  An effective therapeutic compound, there- 
fore, for the treatment of trypanosomiasis of mice and rats  must be 
biologically available within a very short time after its administration 
and must have a  sufficient speed and duration of action to halt and 
eventually overcome a rapidly increasing blood infection comparable, 
in part, with a bacteriemia, which if not checked, will cause the death 
of the animal in a  few days or even hours.  On the other hand, try- 
panosomiasis of many of the larger animals, especially of the rabbit, 
is preeminently a  tissue infection and is characterized, in the acute 
stages, by conspicuous edematous and inflammatory swellings of the 
soft parts,  particularly of the head and external genitalia,  together 
with loss of appetite,  weakness, and emaciation, while in the more 
chronic phases of the infection, the inflammatory lesions undergo in- 
duration and even necrosis with involvement of the deeper tissues in- 
cluding the periosteum and bone.  The duration of the infection in 
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rabbits is a matter of weeks or months and the presence or absence of 
trypanosomes in the blood stream is distinctly of minor importance. 
It is obvious that a drug which is used for the treatment of this type 
of infection must possess in addition to trypanocidal action, the power 
of penetrating diseased tissue,  and since this may require a  consid- 
erable amount of time, the drug in question must remain biologically 
active in the animal host as long as may be necessary. 
In order,  therefore, to  arrive  at  a  full appreciation of the thera- 
peutic  action  of  a  drug  in  experimental trypanosomiasis,  one  has, 
from the point of view of the animal factor, two general types of in- 
fection,  the  treatment of which will  furnish information as  to  the 
speed of action on the one hand and as to the duration of action or 
potency of the drug on the other.  This information, which should 
include such data as the determination of a  therapeutic range in dif- 
ferent animal species as well as curative doses, the therapeutic action 
against different species of trypanosomes, the comparative value of 
different routes of administration, and the results of a  repeated dose 
system of therapy, together with the data upon the toxicological and 
pathological action of the drug in question in various animal species, 
furnishes a  logical foundation for an accurate appraisal of the action 
of  the  drug  under  experimental laboratory  conditions  and,  at  the 
same time, furnishes a  basis for estimating its probable value in the 
treatment of trypanosomal infections as they occur in nature. 
The present paper includes the therapeutic results obtained with 
the amide of N-phenylglycine-p-arsonic  acid in experimental trypano- 
somiasis of mice, rats,  and  guinea  pigs.  While  trypanosomiasis  of 
guinea pigs is,  strictly speaking, a  chronic infection  of  cyclic char- 
acter, the  results  of  its  treatment with  this  drug  are incorporated 
with those of acute infections of mice and rats. 
EXPERIMENTAL. 
Strains of Tr. brucd,  Tr. gambiense, Tr. equinum, Tr. equiperdum, 
and Tr. evansi, carried constantly in stock mice and stock guinea pigs, 
were used for the infecting organisms, and all inoculations were made 
intraperitoneally.  The details of animal inoculation for therapeutic 
purposes and the general conduct of such experiments have been de- LOUISE  PEARCE  AND  WADE  H.  BROWN  439 
scribed  1 and need not be repeated here; but in this connection, mention 
may be made of the desirability of regulating and maintaining a uni- 
form grade of infection, a  factor of importance in interpreting thera- 
peutic results.  In the majority of experiments, we used a  strain of 
Tr. brucei which is highly virulent and uniformly fatal for mice, rats, 
and guinea pigs, mice dying in from 60 to 70 hours, rats in from 4 to 
5  days, and guinea pigs on an average of 4  weeks after the usual in- 
traperitoneal inoculation.  With organisms of less virulence, the size 
of the inoculating dose was proportionately adjusted to insure an in- 
fection comparable with that produced by our strain of Tr.  brucei. 2 
Both mice and rats were treated 18 to 24 hours and guinea pigs usually 
1 week after inoculation,  after parasites  had been demonstrated in 
the peripheral blood.  All the untreated controls died irrespective of 
the  species  of  trypanosome used.  Daily examinations of the blood 
were made in the mouse experiments for the 1st week or 10 days and 
at frequent intervals thereafter, while with rats and guinea pigs, the 
examinations usually began with 2 day intervals.  The treated animals 
were kept under observation from 1 to 3 months. 
Doses of the drug used are expressed in grams of the sodium salt 
per kilo of body weight.  The solutions were always freshly prepared 
with sterile distilled water in various concentrations (0.5,  1, and 2 per 
cent) and the intraperitoneal route of administration was usually em- 
ployed.  The concentration of the drug solution in any given experi- 
ment remained a constant, the volume of the dose being the variable 
quantity. 
Treatment of Experimental Trypanosomiasis of Mice. 
For convenience of comparison, we have summarized, in the accom- 
panying tables, the various protocols of individual experiments which 
were undertaken for the purpose of ascertaining the range of thera- 
peutic  action  of  the  drug.  We  have  included  under  the  heading 
"intercurrent  deaths"  those  animals  which  died  from  accidental 
1  Pearce, L., and Brown, W. H., J. Exp. Med., 1918, xxviii, 109. 
2 In the case of Tr. equinum, the infection produced in several mouse and 
rabbit  experiments was of an unusually severe nature,  a condition which may 
be referable to an increase in the virulence of the strain at the time of inoculation 
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causes within  the  first  15  days  after  treatment  in  the  cases  of  Tr. 
brucei, Tr. gambiense, and Tr. equinum,  and within  the first 30 days 
in the cases of Tr. equiperdum and Tr. evansi, since it was found that 
relapses practically always occurred within these periods of time with 
our strains of these species of trypanosomes, and none of the animals 
listed under "intercurrent deaths" is included in the number of cured 
animals irrespective of the size of the dose administered. 
Trypanosoma  brucei.--Table I  shows the results of the treatment of 
Tr.  brucei infection  in  75  mice  with  graded  doses  of  the  amide  of 
TABLE  I. 
Tr. brucei Infection of Mice Treated with N-Pkenylglycineamide-p-Arsonic  Acid 24 
Hours after Inoculation.  Intraperitoneal Administration. 
Dose per kilo.  No. of mice.  No. of intercurrcut  No. of relapses.  No. of cures. 
deaths. 
gm. 
1.0 
0.9 
0.75 
0.6 
0.5 
0.4 
0.35 
0.3 
0.275 
0.25 
0.225 
0.2 
0.15 
2 
2 
2 
3 
1 
2 
1 
11 
5 
19 
13 
13 
1 
Total .........  75 
2 
2 
2 
3 
1 
1 
1 
10 
5 
16 
10 
5 
0 
N-phenylglycine-p-arsonic  acid ranging from 0.15 to 1 gm. per kilo of 
body weight administered intraperitoneally.  The majority of animals 
were treated with doses of from 0.2 to 0.3 gm., since doses above this 
level seemed uniformly curative,  and in fact, no relapse was demon- 
strable with amounts of 0.275  gm. or more.  Two mice, one treated 
with 0.4 gm. and the other with 0.3 gin., died from accidental causes 
within  the first  15  days and  consequently were not included  in the 
number  of'cured  animals,  although  in  neither  case  could  trypano- LOUISE PEARCE AND  WADE  H. BROWN  441 
somes be demonstrated.  All the other mice which were treated with 
doses ranging from 0.275 to 1 gm. showed no relapse and all lived 30 
days after treatment.  Doses of 0.2, 0.225, and 0.25 gin. per kilo of 
body weight were found to  exert a  definite therapeutic action,  al- 
though at these levels relapses occurred.  With 0.25 gm., two out of 
nineteen mice relapsed and one died from intercurrent causes; with 
0.225 gin., three relapses occurred out of thirteen mice; with 0.2 gin., 
there  were  eight  relapses  out  of  thirteen  treated  animals.  With 
doses at this level,  relapses usually appeared from 3 to 9 days after 
treatment.  In  some  instances  with  doses  of  0.2  and  0.225 g-re., 
parasites were never completely cleared from the blood but they were 
definitely less numerous than in the blood of the untreated controls, 
and in addition, these mice lived longer than the controls. 
TABLE  IX. 
Tr. brucei InfecHon of Mice Treated wittt N.Phenylglycineamide-p-Arsonic Acid 24 
Hours after Inoculation.  Intravenous Administration. 
Dose per kilo.  No. of mice.  No. of intercurrent  deaths.  No. of relapses.  No. of cures. 
gm. 
0.fi 
0.5 
0.4 
0.3 
0.25 
0.2 
0.15 
0.1 
0.05 
0.025 
Total .........  11 
The number of mice treated intravenously and  subcutaneously, 
shown in Tables II and III, is relatively small, yet the therapeutic 
results by such routes are in striking accord with those obtained by 
intraperitoneal administration of the drug.  Of eleven mice treated 
intravenously with  doses  ranging  from 0.025 to  0.6  gm.  per kilo, 
four animals which were given doses  of 0.025, 0.05,  0.1,  and 0.15 
gm. respectively were not cured and the blood of those receiving the 
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which was treated with 0.15 gin.  relapsed on the 4th day.  Doses of 
0.2  gin.  and  above  were  uniformly  curative  as  contrasted  with 
the slightly higher level of 0.275 gin. by intraperitoneal administration. 
Fourteen mice were treated subcutaneously, as indicated in Table 
III,  with doses of 0.2, 0.25,  and 0.3  gin.  with no relapses,  although 
there was one intercurrent  death in  the first fortnight  which is not 
TABLE  III. 
Tr. brucei Infection of Mice Treated  with N-Phenylglydneamide-p-Arsonic Acid 24 
Hours after Inoculation.  Subcutaneous  Administration. 
Dose pet kilo.  No. of mice.  No. of intercurrent  deaths.  No. of relapses.  No. of cures. 
0.3  4  0  0  4 
0.25  5  1  0  4 
O.2  5  0  0  5 
Total ..........  14 
included in the number of cures.  From these results, it would seem 
that both intravenous  and subcutaneous routes of administration  of 
the  drug  in  Tr.  brucei  infections of  mice  were  equally  efficacious, 
since in both the  dose of 0.2  gin.  per kilo  of body weight was uni- 
formly  curative,  a  dose  which  represents  the  lower limit  of  thera- 
peutic  action  by intraperitoneal  administration  as  contrasted  with 
the curative dose of 0.275 gin. by this route. 
Trypanosoma  gambiense.--46  mice  infected  with  Tr.  gambiense 
were treated  intraperitoneally  with  doses of the  drug  ranging  from 
0.125  to 0.3  gm.  per kilo  of body weight  (Table IV).  There  were 
four demonstrable relapses; one mouse treated with 0.25 gin. relapsed 
on the  llth  day, one with 0.15  gin.  also on the  llth  day,  and  two 
with 0.125  gin.  on the  14th  day.  Of the fourteen mice which were 
given  doses  of  0.125  and  0.15  gin.,  three  died  within  the  first  15 
days from accidental causes, three definitely relapsed, and eight ani- 
mals  survived  the  30  day period of  cure.  Graded doses from 0.175 
to  0.3  gin.  were given  to  thirty-two mice,  and  of  this  number  but 
one  animal  treated  with  0.25  grn.  relapsed.  The  range  of  thera- 
peutic activity of the amide of N-phenylglycine-p-arsonic acid against 
Tr.  gambiense  infection  in  mice  is  definitely  greater  than  against LOUISE  PEARCE  AND  WADE  H.  BROWN  443 
Tr.  brucei infections,  since doses of 0.15  gin.  failed  to  cure nagana 
mice and doses of 0.2 gm. were curative in  but  five  out of thirteen 
animals. 
TABLE  IV. 
Tr. gamblense Infection of Mice Treated with N-Phenylglycineamide-p-Arsonic  A cid 
24 Hours after Inoculation.  Intraperitoneal Administration. 
Dose per kilo.  No. of mice.  No. of intercurrent  deaths.  No. of relapses.  No. of cures. 
gm. 
0.3 
0.275 
0.25 
0.225 
0.2 
0.175 
0.15 
0.125 
Total .........  46 
1 
0 
0 
1 
0 
1 
2 
1 
Trypanosoma  equinum.--The  results  of  the  treatment  of  Tr. 
equinum infection in mice are shown in Table V.  Twenty-nine mice 
were treated with intraperitoneal  doses of 0.05  to 0.25 gin.  per kilo 
of body weight, with no relapses at 0.2  and 0.25 gin.  Doses of 0.1 
and 0.15 gm. had a distinct therapeutic effect, and seven of the four- 
TABLE  V. 
Tr. equinum Infection  of Mice Treated with N-Phenylglycineamide-p-A rsonic A dd 
24 Hours after Inoculation.  Intraperitoneal Administration. 
No. of intercurrent  Dose per kilo.  No. of mice.  deaths.  No. of relapses.  No. of cures. 
gm. 
0.25 
0.2 
0.15 
0.1 
0.05 
Total ..........  29 
1  $ 
3t 
1 
0 
0 
* Bacterial infection. 
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teen mice treated with these doses were cured, while in some instances, 
the life of the uncured animal was considerably longer than that of 
the untreated control.  A  dose of 0.05  gin.  had no effect whatever 
on the length of the infection or on the number of parasites in the 
peripheral blood in the single instance in which this dose was used. 
Trypanosoma equiperdum.--In  Table VI  are given the results  of 
the treatment of thirty-seven dourine mice with this  arsenical com- 
pound in doses ranging from 0.15  to 0.5 gm. per kilo of body weight. 
The therapeutic action of the drug on infections in mice produced 
by  our  strain  of  Tr.  equiperdum was  quite  irregular.  Relapses 
TABLE  VI. 
Tr.  equiperdura Infection  of Mice  Treated witk N-Pkenylglycineamide-p-Arsonic 
Add 24 Hours after Inoculation.  Intraperitoneal Administration. 
Doseperkilo.  No. ofmice.  No. ofintercurrent  No. of relapses.  No. of cures.  deaths. 
gm. 
0.5 
0.45 
0.4 
0.35 
0.325 
0.3 
0.275 
0.25 
0.225 
0.2 
0.15 
Total .........  37 
3 
2 
3 
5 
1 
4 
1 
2 
1 
2 
1 
occurred with all doses used irrespective of size, from 4  to  15  days 
after treatment, and there were no cures below doses of 0.225  gm., 
although in every instance, even with the lowest doses, the peripheral 
blood  was  cleared of trypanosomes for several days  and  the  mice 
themselves lived from 2 to 8 days longer than the untreated controls. 
On the other hand, there were some cures at doses of 0.2 to 0.3 gin. 
Trypanosoma  evansi.--Thirty  mice  infected  with  Tr.  evansi 
were treated intraperitoneally with the amide of N-phenylglycine-p- 
arsonic  acid  in  doses  ranging  from 0.15  to  0.75  gm.  (Table  VII). LOUISE PEARCE AND WADE H.  BROWN  445 
There  were definite  cures  at  all  doses  above 0.15  gin.  with  no  de- 
monstrable  relapse  above 0.5  gin.  Of  the  four mice  treated  with 
0.75 gin.,  one died within the first 30 days after treatment and three 
were  cured.  With  doses ranging  downward  from 0.5  gm.,  relapses 
occurred  irregularly  in  from  7  to  15  days,  but  the  trypanocidal 
activity of the drug was shown in all instances even with the lowest 
doses,  since  the  blood  was  cleared  of  parasites  for  several  days 
following treatment. 
TABLE  VII. 
Tr. evansi Infection of Mice Treated  witk N-Phenylglydneamide-p-Arsonic Acid 24 
Hours after Inoculation.  Intraper#oneal Administration. 
Dose per kilo. 
gm. 
0.75 
0.5 
0.4 
0.35 
0.3 
0.275 
0.25 
0.225 
0.2 
0.15 
Total .......... 
No. of mice. 
30 
No. of intercurrent 
deaths.  No. of relapses.  No. of cures. 
3 
2 
3 
1 
2 
1 
1 
0 
1 
0 
Treatment of Experimental Trypanosomiasls of Rats. 
The  therapeutic  experiments  with  rats  are  likewise  grouped  in 
tables  according  to  the  various  species of  trypanosomes  employed. 
As  in  the  case  of  the  mice  experiments,  the  animals  listed  under 
"intercurrent  deaths"  are not included in the number of cured ani- 
mals,  irrespective  of  the  time of occurrence of the death  or of the 
size of the dose administered.  Intraperitoneal administration  of the 
drug was employed in every experiment. 
Trypanosoma  brucei.--Thirty-four  rats  infected  with  Tr.  brucel 
were  treated intraperitoneally with the amide of N-phenylglycine-p- 
arsonic acid in doses of from 0.2 to 1.25  gin. per kilo of body weight 
(Table VIII).  There was but one demonstrable relapse at 0.225 gin. 446  TRYPANOSOM_E  AND  SPIROCHETE  INFECTIOI~S 
in an  animal which showed numerous trypanosomes in its blood 14 
days after treatment.  With doses of the drug as high as 0.75  gin., 
rats may show an early and severe intoxication from which recovery 
is  unusual,  and  such was  the  case with  the  rat which was  treated 
with 0.9 gin.  and which died on the 4th day.  Doses below 0.6 gin. 
are  well  borne  and  are  uniformly curative  in  Tr.  brucei  infections 
down to 0.25 gin.  However, with doses below this level, the thera- 
peutic  action  of  the  drug  is  still  marked  as  shown  by  the  single 
relapse in five animals treated with 0.2  and 0.225  gm. doses. 
TABLE  VIII. 
Tr. brucei Infection of Rats Treated with N-Phenylglycineamide-p-Arsonic Acid 24 
Hours after Inoculation.  Intraperitoneal  Administration. 
Dose per kilo. 
gm. 
1.25 
1.0 
0.9 
0.75 
0.6 
0.5 
0.4 
0.375 
0.35 
0.325 
0.3 
0.275 
0.25 
0.225 
0.2 
Total. 
No. of rats. 
34 
No. ofintercurrent 
deaths. 
0 
0 
1 
0 
1 
1 
0 
0 
2 
0 
1" 
2* 
0 
0 
1 
No. ofrelapses.  No, ofcures. 
* Two pregnant females dying 7 and 8 days after treatment. 
Trypanosoma gambiense.--Table IX shows the results of the treat- 
ment of twenty-five rats  infected with  Tr.  gambiense  with doses of 
from 0.1  to 0.3  gm.  Doses  of 0.2  gm.  and  above were uniformly 
curative,  no  relapses  occurring in  the  fifteen animals  treated  with 
0.2,  0.25,  and 0.3  gm.  per kilo of body weight.  Ten animals  were 
given 0.1  and 0.15  gm. doses, and  of this  number,  there were three 
relapses and one accidental death.  One rat which was treated with LOUISE  PEARCE  AND  WADE  H.  BROWN  447 
0.15  gm.  showed  a  well developed blood infection on  the  18th  day 
and died on the 25th day after treatment.  The two rats which re- 
lapsed with doses of 0.1  gm.  showed trypanosomes on the  10th  and 
18th days and died on the 25th and 36th days. 
TABLE  IX. 
Tr. gambiense Infection of Rats Treated with N-Phenylglycineamide-p-Arsonic  Acid 
24 Hours after Inoculation.  Intraperltoneal Administration. 
Dose per kilo. 
gm. 
0.3 
0.25 
0.2 
0.15 
0.1 
Total .......... 
No. of rats. 
25 
No. of intercurrent 
deaths. 
0 
2 
2* 
1 
0 
No. of relapses.  No. of cures• 
* Animals missing. 
Trypanosoma equiperdum.--Eight rats infected with Tr. equiperdum 
were  treated  with  the  amide  of  N-phenylglycine-p-arsonic  acid  as 
shown in Table X.  Doses from  0.25  to  0.5  gin.  per kilo  of  body 
weight were used and no relapse occurred in the higher doses of 0.4 
and 0.5 gin.  Two rats  treated  with 0.3 gm. relapsed on the 8th and 
16th  days  and one with 0.25 gin.  relapsed on the 7th day.  In each 
case,  however, examination of the peripheral  blood showed no para- 
sites  for  several  days  and  the  animals  all  lived  longer  than  the 
untreated  controls. 
TABLE  X. 
Tr.  equiperdum Infection  of Rats  Treated with N-Phenylglycineamide-p-Arsonic 
Acid  24 Hours after Inoculation.  Intraperitoneal Administration. 
Dose per kilo. 
0.5 
0.4 
0.3 
0.25 
No. of rats,  No. of intc~urrent 
deaths.  No. of relapses.  No. of cures. 
2 
2 
0 
0 
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Trypanosoma  evansi.--The  results  of  the  treatment  of  surra  in- 
fectfon in rats are shown in Table XI.  Nine rats were treated with 
doses ranging  from 0.25 to 0.5 gin. per kilo of body weight, and no 
relapses were observed with doses above 0.25 gin.  Of the three rats 
which were given 0.25  gin.  of the drug,  one relapsed with  a  heavy 
blood infection on the 14th day after treatment and died on the fol- 
lowing day; a  second animal which died on the  14th day showed at 
autopsy  a  large  splenic  tumor  and was  considered  a  probable  re- 
lapse;  while  the  third  rat  in  this  group,  which  died  13  days  after 
treatment,  is not  counted  as a  cured  animal,  although  no parasites 
were  found  in  the  peripheral  blood and  the  autopsy findings  were 
negative. 
TABLE XI. 
Tr. e~ansi Infection of Rats Treated with N-Phenylglycineamide-p-Arsonic A cid 24 
Hours after Inoculation.  Intraperitoneal Admlnis~ration. 
Dose per kilo.  No. of rats.  No. of intercurrent  No. of relapses.  No. of cures.  deaths. 
gm. 
0.5 
0.4 
0.3 
0.25 
Total .........  9 
* Pregnant female. 
1" 
o 
o 
1 
Treatment  of Experimental  Trypanosomiasis  of Guinea Pigs. 
A  number  of  therapeutic  experiments  in  guinea  pigs  have  been 
done of which the example given in Table XII is typical.  Doses of 
0.15,  0.2,  and  0.25  gin.  per  kilo  of body weight  of  the  compound 
given intraperitoneaUy in a  2 per cent solution were uniformly cura- 
tive,  no  relapses  having  been detected  during  the period  of  obser- 
vation of 3 months.  The nagana infection in this particular  experi- 
ment was severe,  as shown by the death  of the  control animals  on 
the  1st  and  3rd  days  after  treatment  of the series.  Other experi- 
ments  in  which  the same  and  much  larger  doses of  the  drug  were 
given  showed uniformly  curative  results  and  need  not  be included 
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The  therapeutic  action  of  N-phenylglycineamide-p-arsonic acid 
upon  experimental  trypanosomiasis  of  guinea  pigs  is  in  striking 
accord with that obtained in mice and rats and in marked contrast 
to  that of many trypanocidal  drugs which show a  greatly lessened 
therapeutic action in this animal species. 
TABLE  XII. 
Tr. brucei Infection  of Guinea Pigs Treated with N-Pkenylglycineamide-p-Arsonic 
Acid 24 Hours after Inoculation.  Intraperitoneal Administration. 
Dose per kilo. 
gm. 
0.25 
0.2 
0.15 
Total .... 
No. of guinea pigs.  No. of intercurrent 
deaths.  No. of relapses.  ~0. of Cllres. 
DISCUSSION. 
As has been shown in the accompanying tables, the curative level 
of the amide of N-phenylglycine-p-arsonic acid is quite constant and 
uniform for most species of trypanosome infections in both mice and 
rats.  Certain exceptions exist which will be referred to later, but in 
general, with the more virulent strains of organisms and the grade of 
infection which we have used, single doses of from 0.2 to 0.3 gin. per 
kilo  of body weight given intraperitoneally 24 hours after inocula- 
tion  are  uniformly  curative.  The  parasites  promptly  disappear 
from the peripheral blood within 24 hours following treatment at this 
level of dosage and barring death from accidental causes, the animals 
survive the observation period of 1 or 2 months with no return of the 
infection.  For mice the minimum lethal dose of this drug given in- 
traperitoneally has  been placed  at 2 to 2.25  gin.  per kilo  of body 
weight, and since the curative dose may be considered as 0.275 gin., 
we  have  a  curative  ratio  of  1:8~  Similarly  the  minimum lethal 
dose of the drug for rats has been estimated at 0.75 gm. per kilo of 
body weight, and the curative ratio for rats, therefore, is 1 : 3. 
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dose that will temporarily clear the blood of trypanosomes as well as 
effect a certain proportion of cures, varies somewhat with the species 
of organism.  Generally speaking, with the more virulent and more 
rapidly fatal trypanosomes, the clearing dose closely approaches the 
curative dose.  Thus, with Tr. brucei infections in mice, 0.2,  0.225, 
and 0.25  gin. were usually clearing doses; while with Tr. gambiense 
and Tr. equinum,  0.1,  0.125,  and 0.15 gin. cleared the blood.  On the 
other hand, with less  virulent strains,  such as  Tr.  equiperdum  and 
Tr. evansi, the cleating dose is considerably below the curative level. 
Thus, with these strains, doses of 0.15  to 0.25  gm. cleared the blood 
of  trypanosomes  for  several  days,  although  the  curative  dose  for 
both strains must be placed above 0.5 gin.  The range of therapeutic 
activity as expressed in  the size of the clearing dose is practically 
the same in the rat as in the mouse infections. 
Different species of trypanosomes vary considerably in  their  re- 
sistance to  therapeutic agents,  and in  this  respect,  the therapeutic 
action of this compound is not maintained at the constant curative 
level of 0.2 to 0.3 gm. per kilo of body weight.  Moreover, the ani- 
mal species employed may to  some extent influence the control of 
certain infections.  The curative range of 0.2 to 0.3 gin. is quite con- 
stant  for  Tr.  brucei, Tr.  gambiense, and  Tr.  equinum  infections in 
mice and  Tr.  brucei and  Tr. gambiense infections in rats,  but with 
Tr. equiperdum and Tr. evansi infections in mice, the dose required 
to effect a  cure is considerably higher.  The highest dose used, 0.5 
gin., failed to cure all the mice infected with Tr. equiperdum, although 
there were cures at doses as low as 0.225  and 0.25 gin.  With infec- 
tions of Tr. evansi, mice treated with 0.75  gin. did not relapse, but 
below this level, cures were uncertain.  Both these infections, how- 
ever, were more easily handled in rats than in mice, since there were no 
relapses with doses of 0.4 gm. in Tr. equiperdum and none with 0.3 
gm. in Tr. evansi infections. 
The lower level of therapeutic action of the drug is  quite sharp 
with the more virulent species of trypanosomes.  Relapses with Tr. 
brucei infections in mice occurred with 0.25  gm. (intrapetitoneal ad- 
ministration) and increased in number with lower doses, while with Tr. 
gambiense and  Tr.  equinum  infections in mice, relapses began with 
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relapsed with a 0.25 gin. dose.  It is possible that  this relapse might 
have been due to a  leakage of the drug at the time of treatment, since 
this was the only observed relapse in twenty-eight mice treated with 
doses of  from 0.175  to  0.25  gin.  The  majority  of  relapses  with 
these infections occurred from 5  to  12  days after  treatment.  The 
level of relapse occurrence with Tr.  brucei and Tr. gambiense infec- 
tions in rats is quite comparable with that observed in  mice, while 
the  time  of  occurrence was  from  14  to  25  days  after  treatment. 
With  the less  virulent organisms which were used,  Tr.  equiperdum 
and Tr. evansi, the therapeutic action of the amide of N-phenylglycine- 
p-arsonic acid is much less clear-cut and regular.  Relapses occurred 
in mice with doses of from 0.15  to 0.5 grn. and in general from 7 to 
15 days after treatment.  The therapeutic action in rats, however, is 
more constant and more sharply limited, for with  Tr.  equiperdum 
infections, there were no relapses above 0.3 gm. and with Tr. evansi 
none above 0.25  gin.  The relapses with both these species in rats 
occurred from 8 to 16 days after treatment.  It will be recalled that 
in all the experiments with both mice and rats,  and irrespective of 
the species of  trypanosome employed, treatment was given on the 
day following the inoculation of the animals and that the therapeutic 
results described above apply to the treatment of a 24 hour infection. 
The average curative level, the clearing dose, and the number and 
time of relapses would undoubtedly be affected with any considerable 
change in the time of treatment. 
The therapeutic results in the treatment of experimental trypano- 
somiasis of guinea pigs, as shown by the low curative dose of 0.15 gin. 
per kilo of body weight in a severe infection, .are even better than those 
obtained inthe treatment of mice and rats and are in striking contrast 
to the action of certain other trypanocidal agents.  The curative ratio 
expressed in fractions of the minimum lethal dose is 1: 10, since the 
lethal dose for guinea pigs is 1.5 gin. per kilo of body weight given 
intraperitoneally or subcutaneously. 
The rapidity of the trypanocidal action of the amide of N-phenyl- 
glyclne-p-arsonic acid on trypanosomiasis of mice, rats,  and guinea 
pigs is quite marked.  That is, with curative doses, the drug becomes 
quickly available  after its  administration and remains in  an active 
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in  18  to  24  hours  after the  treatment of a  24  hour infection, the 
peripheral blood is  free of parasites.  Moreover, with  subcurative 
but  clearing doses,  a  similar speed of trypanocidal action is shown. 
This speed of trypanocidal activity is operative in both mice and rats, 
but in the case of our strains of Tr. equiperdum  and Tr. evansi,  the 
action is  apparently somewhat more drastic in rats.  In mice the 
therapeutic action extends over a wide range of doses and cures are 
irregularly distributed  among the low  as  well  as  among the  high 
limits of this range, while treatment of the same infections in rats 
reveals a more sharply limited therapeutic action.  It is of interest 
in this connection to  compare the  results  of  the adm~nlstration of 
the drug by different routes in the treatment of Tr. brucei infections 
of mice.  By all three routes, intraperitoneal, intravenous, and sub- 
cutaneous, the sharpness of therapeutic action is maintained within 
the curative range and apparently the drug is as available in an active 
biological  state  by  subcutaneous  as  by  intraperitoneal  or  intra- 
venous administration.  The therapeutic experiments in guinea pigs 
are too few to admit final analysis, but apparently the rapidity and 
sharpness  of  action  of  the  drug  likewise  obtain  in  this  animal 
species. 
One other point regarding the action of the drug should be men- 
tioned and this is  in  connection with the general condition of the 
treated animals.  Practically without exception, all  the  cured ani- 
mals showed a marked improvement manifested by a gain in weight 
and by the healthy appearance of their coats which dated from the 
time of treatment and continued during the period of observation. 
The cured animals were usually in a better condition than those of 
the  original stock.  Rats  which were treated with high  doses  ap- 
proaching a  lethal level and which developed toxic manifestations 
did not recover, but aside from this evidence of drug toxicity, the 
treated  animals  were  uniformly in  excellent state.  The  negative 
autopsy findings in animals that were treated with therapeatic doses 
of  the  amide of  N-phenylglycine-p-arsonic acid furnish additional 
corroborative evidence of the non-injurious action of such doses to 
the host. LOUISE PEARCE  AND  WADE  H. BROWN  453 
CONCLUSIONS. 
N-Phenylglycineamide~p-arsonic acid is an agent of marked thera- 
peutic  action  in  the  treatment  of  experimental trypanosomiasis of 
mice, rats, and guinea pigs.  It possesses an average curative range 
of from 0.2  to 0,3  gin. per kilo of body weight of the sodium salt 
against  a  24  hour infection in mice and  rats  produced by  several 
species of pathogenic trypanosomes.  Since the lethal dose for mice 
is from 2 to 2.25 gm. and for rats 0.75 gin. per kilo of body weight, 
we have curative ratios of 1:8 and 1:3 respectively.  The  curative 
dose for guinea pigs is 0.15 gin. per kilo of body weight, thus  giving 
a  curative  ratio  of  1: 10.  The  trypanocidal activity of this com- 
pound is relatively rapid in all three animal species, for the periph- 
eral blood is cleared of organisms within 24 hours after its admin- 
istration, and in addition, the lower limits of the curative range are 
comparatively  sharply  defined.  Intraperitoneal,  intravenous,  and 
subcutaneous routes of administration for all practical purposes may 
be considered equally efificacious in Tr. brucei infections of mice both 
as regards the speed of action of the drug and the average curative 
range.  The ,~dministration of the drug in therapeutic amounts in 
all three animal species is not followed by manifestations of organic 
or functional injury, but, on the contrary, the genera] physical con- 
clifton  of  the  treated  animals  shows  an immediate and  continued 
marked improvement. 
The  therapeutic  activity  in  trypanosomiasis  of  mice,  rats,  and 
guinea pigs  as  evidenced by  the  relative  speed  and  sharpness  of 
action, together with the curative ratio as expressed in fractions  of 
the minimum lethal dose, and the absence of organic injury or func- 
tional  disturbance  following  therapeutic  doses  are  significant  and 
characteristic features of the amide of N-phenylglycine-p-arsonic acid. 